AI for Batch Record Review by Exception
: The Future of Pharmaceutical Batch Release? A Practical GMP Perspective on AI Batch Review, Electronic Batch Records, and Quality Oversight Batch record review is one of the most important and time-sensitive activities in pharmaceutical Quality Assurance. Before a batch can be released or distributed, the Quality Unit must review production and control records to determine whether the batch was manufactured according to approved procedures and whether any discrepancies, deviations, or failures were properly investigated. This is not optional. FDA requires batch production and control records to be prepared for each batch and to include complete information related to the production and control of that batch, including equipment used, components, in-process and laboratory control results, yields, labeling records, sampling, checks, and investigations where applicable (FDA, 21 CFR 211.188). FDA also requires all drug product production and control records, including packaging and labeling records, to be reviewed and approved by the Quality Control Unit before batch release or distribution (FDA, 21 CFR 211.192). The challenge is that traditional batch record review is slow, repetitive, and heavily dependent on human attention. Reviewers must examine pages of entries, signatures, calculations, timestamps, corrections, attachments, alarms, deviations, equipment IDs, reconciliation records, and procedural confirmations. In paper or hybrid systems, this can take hours or days per batch. Even in electronic batch record systems, reviewers may still spend significant time verifying routine steps that were already executed within validated workflows. This is where review by exception becomes attractive. Instead of manually reviewing every routine entry with equal intensity, QA focuses on exceptions: deviations, missing entries, invalid signatures, parameter excursions, yield discrepancies, unapproved interventions, late entries, alarm events, reconciliation mismatches, and unusual process patterns. AI could take this concept further by helping detect anomalies, prioritize batch review risks, correlate process data, and identify records that deserve deeper QA attention. But AI should not become the batch release decision-maker. In GMP, batch disposition remains a Quality Unit responsibility.
What Is Batch Record Review?
Batch record review is the process of verifying that the batch was manufactured, processed, packed, tested, and documented according to approved procedures and specifications.
| Review Area | Examples |
|---|---|
| Manufacturing steps | Verification that each required step was completed |
| Equipment and line use | Correct equipment ID, line clearance, cleaning status, setup |
Materials and components Correct lot numbers, quantities, reconciliation, expiry status Process parameters Temperature, pressure, speed, time, mixing, hold times In-process controls Fill weight, pH, bioburden, appearance, torque, hardness Laboratory results Finished product testing, in-process testing, stability if applicable Yield reconciliation Actual yield, theoretical yield, acceptable yield range Packaging and labeling Label reconciliation, specimen labels, coding, line clearance Deviations Investigation, product impact, CAPA, batch disposition support Signatures and checks Operator entries, supervisor checks, QA verifications Data integrity Corrections, late entries, audit trails, missing data, unexplained changes The purpose is not paperwork perfection. The purpose is documented assurance that the batch was made correctly and that any unexplained discrepancy or failure was investigated before release.
Why Traditional Batch Record Review Is So Difficult
Traditional batch review is difficult because it combines compliance review, technical review, documentation review, and product quality assessment.
| Challenge | Practical Impact |
|---|---|
| Large record volume | QA spends time reviewing routine entries instead of focusing on risk |
| Paper-based records | Manual page-by-page review increases cycle time |
| Hybrid records | Paper, MES, LIMS, SCADA, QMS, and spreadsheets must be reconciled |
| Human fatigue | Reviewers may miss small but important errors |
| Manual calculations | Yield, reconciliation, and in-process calculations may be error-prone |
| Late deviations | Issues may be found at final QA review instead of during manufacturing |
| Missing attachments | Cleaning records, labels, printouts, or logs may delay release |
| Audit trail review burden | Electronic data require meaningful audit trail review |
| Unclear exceptions | Not all deviations carry equal product risk |
| Release pressure | Commercial demand may create pressure to complete review quickly |
What Is Review by Exception?
Review by exception is a quality review model where routine, compliant, system-verified entries receive less manual attention, while exceptions receive focused review.
In an electronic batch record environment, review by exception may involve system rules such as: Required field not completed Step performed out of sequence Parameter outside approved range Missing electronic signature Unauthorized user action Late entry Manual override Equipment not qualified or available Material lot not approved Yield outside expected range Alarm during critical step Deviation linked to batch Audit trail event requiring review Instead of asking QA to manually confirm every expected entry, the system highlights what is unusual, incomplete, or potentially GMP-impacting. Manufacturing executes batch ↓ Electronic system captures steps, parameters, signatures, and timestamps ↓ System applies predefined exception rules ↓ Exceptions are flagged in real time or during review ↓ Manufacturing/QA resolve or investigate exceptions ↓ QA reviews exception summary plus required critical records ↓ Quality Unit approves or rejects batch disposition This model can reduce review time, but only if the system is validated, the exception rules are scientifically justified, and QA retains final release authority.
Why AI Could Improve Review by Exception
Traditional review-by-exception systems depend on predefined rules. These rules are valuable, but they often detect only known issues. AI can potentially strengthen review by exception by detecting unusual patterns that may not be captured by fixed rules.
| Traditional Rule | AI-Enhanced Detection |
|---|---|
| Temperature exceeded limit | Temperature remained within limit but showed abnormal oscillation |
| Yield outside range | Yield within range but trending lower across recent batches |
| Step completed late | Multiple small delays occurred in the same process phase |
| Deviation opened | Similar near-miss patterns occurred without formal deviation |
| Alarm triggered | Alarm pattern resembles prior batch failure signature |
| Manual override used | Override occurred under unusual |
operator/equipment/context pattern Missing signature Signature present but timing pattern suggests review after-the-fact In-process result within limit Result is within specification but statistically unusual for this product The value of AI is not simply faster review. The value is more intelligent review: helping QA focus attention where product quality risk may be higher.
AI Anomaly Detection in Batch Records
AI anomaly detection can identify batch record events or data patterns that differ from expected behavior.
| Anomaly Type | Example |
|---|---|
| Process anomaly | Mixing time normal, but torque profile unusual |
| Timing anomaly | Step duration significantly longer than historical norm |
| Operator anomaly | Unusual number of corrections by one operator or shift |
| Equipment anomaly | Higher frequency of minor alarms on same filling line |
| Material anomaly | Specific component lot linked to repeated adjustments |
| Documentation anomaly | Entries completed unusually late compared with process timestamps |
| Yield anomaly | Yield still within limits but drifting downward over multiple batches |
| Audit trail anomaly | Repeated value changes before final entry acceptance |
Electronic Batch Records and AI
AI works best when batch data are structured, time-stamped, and electronically available. Electronic batch record systems can capture data from: MES EBR workflows LIMS SCADA PLCs Equipment historians Weighing and dispensing systems Barcode systems Labeling systems Environmental monitoring systems
QMS deviations and CAPAs CMMS and calibration systems A mature AI-assisted review-by-exception program could analyze:
| Data Source | AI Review Use |
|---|---|
| MES/EBR | Step execution, signatures, timing, sequence |
| LIMS | In-process and finished product test results |
| SCADA/historian | Process parameter profiles and alarms |
| QMS | Deviations, investigations, CAPAs linked to batch |
| CMMS | Equipment maintenance history relevant to batch |
| Calibration system | Instrument status during batch execution |
| EM system | Environmental conditions during sterile manufacturing |
| Labeling system | Label reconciliation and coding verification |
| ERP/material system | Material status, supplier lot, inventory movement |
Manufacturing Examples
Example 1: AI Flags a Subtle Filling Line Pattern
A sterile filling batch has no critical deviations. Fill weights are within limits. However, AI detects that the line had more micro-stoppages than usual, increased operator interventions during stopper feeding, and a slightly wider fill-weight distribution than the product baseline. QA reviews the AI signal and requests additional review of interventions, EM data, equipment alarms, and rejected units. No product impact is identified, but engineering opens a maintenance work order for stopper bowl adjustment. GMP value: AI identifies a weak operational signal before it becomes a deviation trend.
Example 2: AI Detects a Documentation Timing Issue
An EBR shows all required signatures completed. AI compares process timestamps with signature timestamps and flags that multiple checks were signed significantly later than expected, all by the same shift. QA reviews the audit trail and determines whether this represents acceptable delayed documentation, a procedural gap, or a data integrity concern. GMP value: AI supports meaningful review of documentation behavior, not just completion status.
Example 3: AI Connects Yield Drift With Equipment History
A tablet compression process remains within yield limits, but AI detects a downward yield trend across five batches. It correlates the trend with increased reject counts and a recent tooling change. QA and manufacturing review batch data, equipment setup, and change control records. The issue is corrected before a batch falls outside expected yield.
GMP value: AI strengthens review by exception by detecting trends that are not yet formal exceptions.
Example 4: AI Prioritizes Batch Review Workload
A QA team has ten batches awaiting review. AI ranks them based on exception count, deviation severity, audit trail events, parameter anomalies, and unresolved linked records. Batches with no exceptions and low-risk profiles are reviewed efficiently. Batches with unusual patterns receive deeper QA review. GMP value: AI helps allocate reviewer attention based on risk.
Regulatory Analysis: FDA Expectations
AI-assisted batch review must begin with the basic regulatory expectation: batch production and control records must be complete and reviewed before release. FDA’s 21 CFR 211.188 requires batch production and control records for each batch and lists required record content such as equipment used, component lots, weights and measures, in-process and lab results, packaging and labeling inspection, yields, labeling records, sampling, checks, and investigations (FDA, 21 CFR 211.188). FDA’s 21 CFR 211.192 requires all drug product production and control records, including packaging and labeling records, to be reviewed and approved by the Quality Control Unit before a batch is released or distributed. It also requires unexplained discrepancies or batch/component failures to be thoroughly investigated, even if the batch has already been distributed (FDA, 21 CFR 211.192). That means AI can assist review, but it cannot remove the Quality Unit’s responsibility. A company must still demonstrate: Required records exist Records are complete Exceptions are identified Discrepancies are investigated Product impact is assessed Batch disposition is justified Quality Unit approval occurs before release AI may help make this review more efficient, but it does not weaken the regulatory obligation.
Data Integrity and Audit Trail Implications
Batch record review by exception becomes more complex when records are electronic. FDA Part 11 establishes requirements for electronic records and electronic signatures, including controls intended to ensure records are trustworthy and reliable (FDA, 21 CFR Part 11). FDA’s data integrity guidance also emphasizes that CGMP records must be complete and accurate, and the guidance is specifically focused on data integrity and compliance with drug CGMP (FDA, 2018). Data Integrity Question Why It Matters
| What source data did AI review? | QA must know whether EBR, LIMS, SCADA, QMS, and audit trails were included |
|---|---|
| Was source data complete? | Missing historian or LIMS data could hide exceptions |
| Was the AI output retained? | Batch review rationale must be reconstructable |
| Were AI flags accepted or rejected? | Human review decisions should be documented |
| Was the model version controlled? | Different model versions may flag different exceptions |
| Were audit trail events reviewed? | AI should not replace required audit trail review strategy |
| Can inspectors see the evidence? | Inspection readiness requires traceability |
EMA and EU GMP Considerations
EU GMP Annex 11 applies to computerized systems used as part of GMP-regulated activities. It was revised in response to increased use and complexity of computerized systems (European Commission, Annex 11). If an AI-enabled EBR or review-by-exception tool is part of GMP batch review, Annex 11 expectations around validation, control, access, data integrity, and system lifecycle should be considered. EMA’s reflection paper on AI states that AI/ML tools can support acquisition, transformation, analysis, and interpretation of data when developed and used correctly. It also emphasizes a risk-based approach for development, deployment, and performance monitoring, and states that risk depends not only on the technology and data quality, but also on context of use and the degree of influence the AI exerts (EMA, 2024).
| AI Use | Regulatory Risk |
|---|---|
| AI highlights possible exceptions for QA review | Moderate, if controlled and validated |
| AI prioritizes review workload | Moderate, depending on impact |
| AI drafts batch review summary | Moderate to high, if used in release documentation |
| AI determines whether a deviation is needed | High |
| AI recommends batch release | Very high |
| AI automatically releases batch | Not appropriate under current GMP expectations |
Validation Requirements for AI Batch Review
An AI-assisted batch review system should be validated according to intended use and risk.
| Validation Element | Practical Question |
|---|---|
| Intended use | Is AI advisory, prioritizing, summarizing, or decision- making? |
| Data inputs | Which systems feed the model: MES, LIMS, QMS, SCADA, CMMS? |
| Data mapping | Are batch IDs, equipment IDs, material lots, and timestamps correctly linked? |
Exception rules Are rule-based exceptions scientifically justified and tested? AI anomaly detection Can the model detect known historical anomalies? False negatives Could AI miss a critical exception? False positives Could excessive alerts create review fatigue? Audit trail Are AI outputs and human decisions retained? Model version control Are model/configuration updates controlled? Access control Can only authorized personnel approve batch review? Electronic signatures Are signatures compliant with applicable requirements? Periodic review Is performance monitored after deployment? The validation approach should be proportional. An AI tool used only for optional dashboard visualization is lower risk than an AI tool that determines review status or generates batch disposition recommendations.
Risk Assessment Table
| AI Batch Review Use Case | GMP Risk | Potential Impact | Required Control |
|---|---|---|---|
| AI flags missing entries | False negative misses incomplete record | Batch released with incomplete documentation | Rule validation and QA review |
| AI detects process anomaly | False positive creates unnecessary investigation | Release delay and investigation burden | SME triage and alert thresholds |
| AI ranks batches by review priority | High-risk batch incorrectly ranked low | QA attention misallocated | Conservative ranking rules and reviewer override |
| AI reviews audit trail patterns | Important audit trail event missed | Data integrity issue overlooked | Defined audit trail review strategy |
| AI drafts batch release summary | Summary omits key exception | Misleading disposition rationale | Human verification against source records |
| AI links deviations to batch | Incorrect linkage | Wrong product impact assessment | Validated data mapping |
| AI predicts batch quality risk | Overreliance on prediction | Incorrect release confidence | Advisory-only use and QA approval |
| AI recommends release | AI conclusion accepted without review | Serious GMP compliance risk | Do not allow autonomous release |
Practical AI-Assisted Batch Review Workflow
Batch executed in MES/EBR ↓ Data captured from EBR, LIMS, SCADA, QMS, and related systems ↓ System applies predefined exception rules ↓ AI performs anomaly detection and pattern comparison ↓ Exception dashboard generated ↓ Manufacturing resolves operational/documentation exceptions ↓
QA reviews critical records, exceptions, deviations, audit trails, and AI findings ↓ QA accepts/rejects AI findings with rationale ↓ Any discrepancy is investigated under approved procedure ↓ Quality Unit approves or rejects batch release ↓ AI model performance reviewed periodically This workflow keeps the Quality Unit in control while making the review process more targeted.
Future Adoption Barriers
AI batch review by exception sounds attractive, but adoption will not be easy.
| Barrier | Explanation |
|---|---|
| Paper batch records | AI needs structured electronic data to perform well |
| Hybrid systems | Data spread across paper, EBR, LIMS, QMS, and spreadsheets |
| Poor master data | Inconsistent equipment, material, and batch identifiers |
| Weak exception definitions | System cannot flag risk if rules are poorly designed |
| Validation burden | AI tools require intended-use-based validation |
| Regulatory uncertainty | Companies may hesitate to use AI near batch release |
| Data integrity concerns | AI outputs must be traceable and reviewable |
| Cultural resistance | QA may not trust automated review support |
| Vendor black boxes | Explainability and documentation may be limited |
| Alert fatigue | Too many AI findings can slow review instead of improving it |
Can AI release pharmaceutical batches?
No. AI should not independently release pharmaceutical batches. FDA requires production and control records to be reviewed and approved by the Quality Control Unit before release or distribution (FDA, 21 CFR 211.192). AI can support review, but the Quality Unit must retain batch disposition authority.
What is review by exception?
Review by exception means focusing QA review on exceptions, discrepancies, missing data, deviations, parameter excursions, audit trail concerns, and unusual patterns rather than manually reviewing every routine compliant entry with the same intensity.
Is review by exception allowed in GMP?
Review by exception can be used when the system is validated, records remain complete, exceptions are properly defined, discrepancies are investigated, and the Quality Unit still reviews and approves
the batch before release. The company must be able to demonstrate control and compliance with applicable GMP requirements.
What is the best first AI use case for batch review?
The best first use case is AI-assisted anomaly detection or exception prioritization in an electronic batch record environment. AI can flag unusual patterns for QA review without making release decisions.
Does Part 11 apply to AI batch review?
Part 11 may apply if the system creates, modifies, maintains, retrieves, or transmits electronic records required under FDA regulations, or uses electronic signatures. AI-enabled EBR workflows should be assessed for Part 11 applicability and validated accordingly (FDA, 21 CFR Part 11).
What is the biggest risk?
The biggest risk is overreliance. If QA assumes “no AI exception” means “no problem,” critical issues may be missed. Traditional GMP review responsibilities and human judgment must remain active.
Can AI help with audit trail review?
Yes, AI can help identify unusual audit trail patterns, late entries, repeated corrections, or unexpected changes. However, the company still needs a defined audit trail review strategy and human review for GMP significance.
Conclusion: AI Can Improve Batch Review, but Batch Release Must Remain a Human GMP Decision
AI for batch record review by exception is one of the most practical and high-impact applications of artificial intelligence in pharmaceutical quality operations. Batch review is repetitive, data-heavy, time-sensitive, and vulnerable to reviewer fatigue. AI can help identify exceptions, detect unusual process patterns, prioritize review workload, and connect batch records with process monitoring, deviations, audit trails, and equipment data. But AI does not replace the Quality Unit. FDA requires complete batch production and control records and Quality Unit review and approval before release or distribution (FDA, 21 CFR 211.188; FDA, 21 CFR 211.192). EMA’s AI reflection paper also reinforces that AI risk depends on context of use and the degree of influence the system exerts (EMA, 2024). The realistic future is not autonomous batch release. The realistic future is smarter QA review: fewer hours spent checking routine compliant entries, more attention on exceptions that actually matter, and stronger traceability for batch disposition decisions. For AIforQA.org, this is a strong cornerstone topic because it addresses a major operational pain point in pharmaceutical QA: how to release batches faster without lowering the standard of GMP review.
References
1. FDA. 21 CFR 211.188 - Batch Production and Control Records. Requires batch production and control records for each batch, including complete production and control information such as
equipment, components, in-process and laboratory results, yields, labeling records, sampling, checks, and investigations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/ subpart-J/section-211.188 2. FDA. 21 CFR 211.192 - Production Record Review. Requires all drug product production and control records, including packaging and labeling, to be reviewed and approved by the Quality Control Unit before release or distribution, and requires unexplained discrepancies or batch failures to be thoroughly investigated. https://www.ecfr.gov/current/title-21/chapter-I/subchapter- C/part-211/subpart-J/section-211.192 3. FDA. 21 CFR Part 11 - Electronic Records; Electronic Signatures. Establishes requirements for electronic records and electronic signatures, including controls for trustworthy and reliable electronic records. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11 4. FDA. Data Integrity and Compliance With Drug CGMP: Questions and Answers - Guidance for Industry. FDA guidance addressing data integrity expectations for drug CGMP records and systems. https://www.fda.gov/media/119267/download 5. European Commission. EudraLex Volume 4, EU GMP Annex 11: Computerised Systems. Provides EU GMP expectations for computerized systems used as part of GMP-regulated activities. https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf 6. European Medicines Agency. Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle. Discusses AI/ML risk-based development, deployment, performance monitoring, context of use, data quality, degree of AI influence, and manufacturer responsibility for fit-for- purpose algorithms, models, datasets, and data processing pipelines. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial- intelligence-ai-medicinal-product-lifecycle_en.pdf